During the first few years of the COVID-19 pandemic, the virus SARS-CoV-2 was detected in an increasing number of non-human animal species. This included many wild animal species as well as domestic ...

You requested an update and elaboration on our previous rapid expert consultation dated March 15, concerning issues of virus survival on surfaces and in the air, and virus/disease incubation period.

UCSF researchers designed new drug candidates that potently block MPro, a viral enzyme that's crucial for SARS-CoV-2 replication. One of these drug candidates, AVI-4516, is shown (center) bound to the ...

How could we forget the SARS-CoV-2 pandemic, right? It’s now part of our history, a story to pass on to the next generation. There are hundreds of related SARS-CoV strains known to infect different ...

A Stanford-led team has found two antibodies that can work together to defeat all SARS-CoV-2 variants. More research is needed, but the approach could help in the development of treatments to keep ...

The global pandemic may be over, but SARS-CoV-2 continues to infect people around the world. Indeed, the United States has recorded roughly 750 deaths from COVID-19 over the past month. Now, an siRNA ...

Since the start of the SARS-CoV-2 pandemic, several variants of the virus have developed into Variants of Concern (VOCs), as classified by the World Health Organization (WHO). VOCs are virus variants ...

Systemic mastocytosis: Statistics and impact of secondary malignancy on survival. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text ...

Since the start of the COVID-19 pandemic, there has been controversy surrounding the origins of SARS-CoV-2. New research from the University of California, San Diego (UCSD), School of Medicine ...